Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Generic Drugs Approvals

Eyes On The Prize: Two More Aflibercept Biosimilars Get EU Nods

Sandoz And Samsung Bioepis Scoop Positive CHMP Opinions For Eylea Rivals

  • News

Executive Summary

In the wake of Biocon’s debut positive opinion for an aflibercept rival to Eylea just over a year ago, two further companies – Sandoz and Samsung Bioepis – have now secured coveted endorsements from the European Medicines Agency for their own versions of the ophthalmic biosimilar. Meanwhile, Teva has received a CHMP nod for another Imnovid generic.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Related Companies

Tags:
Biosimilars Generic Drugs Approvals
Latest Headlines

For Generic Manufactures, New Medicare Drug Pricing Demo Is a Dud

Telmisartan Leads UK Rises In September As Price Surges Subside

Government And Industry Stakeholders Debate Future Of European Drug Supply

ViiV Commits To Tripling Apretude PrEP Supply In Low Income States

See All
UsernamePublicRestriction

Register

GB153803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By